Olema Pharmaceuticals Files 8-K
Ticker: OLMA · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1750284
| Field | Detail |
|---|---|
| Company | Olema Pharmaceuticals, INC. (OLMA) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
Olema Pharma filed a standard 8-K, no major news.
AI Summary
Olema Pharmaceuticals, Inc. filed an 8-K on September 2, 2025, reporting on other events and financial statements. The filing does not contain specific material events or financial figures beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates Olema Pharmaceuticals is meeting its regulatory reporting obligations. It does not disclose new material information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain any new material information or significant events that would inherently increase risk.
Key Players & Entities
- Olema Pharmaceuticals, Inc. (company) — Registrant
- September 02, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 30-0409740 (tax_id) — IRS Employer Identification No.
- 780 Brannan Street (address) — Principal Executive Offices
- San Francisco (city) — Principal Executive Offices
- California (state) — Principal Executive Offices
- 94103 (zip_code) — Principal Executive Offices
- 415 651-3316 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Olema Pharmaceuticals?
The primary purpose of this 8-K filing is to report on other events and financial statements as of September 2, 2025, fulfilling regulatory disclosure requirements.
What specific material event is being disclosed in this 8-K?
This 8-K filing does not specify any particular material event beyond the standard reporting categories of 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits'.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on September 2, 2025.
Where is Olema Pharmaceuticals, Inc. headquartered?
Olema Pharmaceuticals, Inc. is headquartered at 780 Brannan Street, San Francisco, California, 94103.
Does this filing indicate any changes in Olema Pharmaceuticals' financial condition or business operations?
This filing, as presented, does not provide specific details on financial condition or business operations beyond its classification as a routine report including financial statements and exhibits.
Filing Stats: 926 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2025-09-02 07:05:30
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share OLMA The Nasdaq Global Se
Filing Documents
- olma-20250902.htm (8-K) — 50KB
- olma-ex99_1.htm (EX-99.1) — 18KB
- img39466132_0.jpg (GRAPHIC) — 297KB
- 0001750284-25-000007.txt ( ) — 586KB
- olma-20250902.xsd (EX-101.SCH) — 24KB
- olma-20250902_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 2, 2025, Olema Pharmaceuticals, Inc. (the "Company") issued a press release announcing that it had entered into a new clinical trial collaboration and supply agreement (the "Agreement") with Pfizer Inc. ("Pfizer"). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events. As described above, on September 2, 2025, the Company announced that it had entered into the Agreement with Pfizer. Pursuant to the Agreement, the Company and Pfizer will evaluate in a Phase 1b/2 study the safety and combinability of palazestrant plus atirmociclib, Pfizer's investigational, highly selective-CDK4 inhibitor, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative ("ER+/HER2-") metastatic breast cancer. Pfizer will supply atirmociclib for use in the Phase 1b/2 study and the Company will lead the conduct of the study. All clinical data and inventions relating to the combined use of atirmociclib and palazestrant resulting from the study will be jointly owned, with the Company maintaining full global commercial and marketing rights to palazestrant. This Agreement is the Company's second clinical trial agreement with Pfizer. The companies' previous agreement was established in November 2020 to evaluate palazestrant in combination with palbociclib (IBRANCE) in patients with recurrent, locally advanced or metastatic ER+/HER2- breast cancer.
Forward Looking Statements
Forward Looking Statements
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated September 2, 2025, of Olema Pharmaceuticals, Inc . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Olema Pharmaceuticals, Inc. Date: September 2, 2025 By: /s/ Shane Kovacs Shane Kovacs Chief Operating and Financial Officer